S-4363-119
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Sponsored by Tim Kaine (D-VA)
What it does
This bill would do two things. First, it would extend the existing requirement for annual congressional briefings on the National Biodefense Strategy — pushing the deadline from March 2025 to five years after the enactment of the FY2027 National Defense Authorization Act. Second, it would require that the next biennial biodefense threat assessment delivered to Congress include a dedicated analysis of risks posed by engineering biology (such as synthetic biology and genetic engineering), along with recommendations for modernizing biosafety, biosecurity, and biodefense authorities. The recommendations must be developed in consultation with industry, academia, and civil society, and must include proposed legislative actions and funding estimates.
Who benefits
Congress, which would receive more structured and extended oversight information on biodefense. Federal agencies involved in biodefense (e.g., DHS, HHS, DoD) that would receive clearer guidance on aligning research and reducing redundancy. Life sciences researchers who would benefit from a more coherent governance framework for engineering biology. Biotechnology companies that could gain regulatory clarity. The general public, which could benefit from improved national preparedness against engineered biological threats. Independent researchers and civil society organizations explicitly included in the consultation process.
Who is hurt
Federal agencies that may face increased reporting burdens and potential new regulatory requirements stemming from the recommendations. Life sciences researchers and biotechnology firms that could face new or expanded biosafety and biosecurity regulations if the bill's recommendations lead to stricter oversight. Taxpayers who would bear the cost of any new programs or funding recommended by the assessment. Researchers who have received federal grants or contracts in the past five years are explicitly excluded from the consultation process, which may limit the perspectives of the most active federally funded scientists.
Supporters argue
Supporters argue that engineering biology — including synthetic biology and gene editing — is advancing faster than existing regulatory frameworks, creating potential national security and public safety gaps that Congress currently lacks the information to address. They contend that the 2021 National Academies report on biodefense identified engineering biology as an underassessed threat, and that requiring a structured, cross-agency analysis with concrete legislative recommendations is a necessary first step toward closing those gaps. They also argue the bill's consultation requirement — specifically including non-federally-funded researchers — helps ensure independent, unbiased expert input.
Opponents argue
Opponents argue that the bill adds another layer of reporting and assessment requirements to an already complex biodefense bureaucracy without guaranteeing any concrete policy action, potentially producing a lengthy report that sits unused. They contend that existing mechanisms — including the biennial biodefense threat assessment and annual NDAA briefings — already cover biological risks broadly, and that singling out engineering biology without clear statutory definitions of what triggers regulatory action could create regulatory uncertainty that chills legitimate life sciences research and innovation. They further argue that excluding federally funded researchers from consultation may systematically omit the scientists with the deepest technical expertise.
Constitutional context
This bill operates squarely within Congress's national defense and oversight powers under Article I and presents no significant constitutional tension. The Necessary and Proper Clause (Art. I, §8, cl. 18) supports Congress's authority to require executive branch reporting and analysis in support of its legislative and appropriations functions. No Commerce Clause, takings, or major questions doctrine issues are implicated by this reporting and assessment bill.
Checks and balances
The executive branch (specifically covered departments and agencies) gains a structured analytical role in shaping future biodefense legislation, but Congress retains authority by requiring unclassified reporting, mandating consultation with outside stakeholders, and reserving all legislative action for itself based on the recommendations received.
Historical precedent
The original biodefense briefing requirement was established in the National Defense Authorization Act for Fiscal Year 2017, and the biennial biodefense threat assessment framework was created by the FY2021 NDAA — this bill extends and adds to those existing statutory structures.